BridgeBio has substantially boosted its course of an novel therapy for cardiac amyloidosis, employing the compound. Preliminary patient information suggests promising outcomes for patients affected with a debilitating disease. This focus underscores researchers’ commitment to treating unmet medical requirements in this heart disease space. Attru